Skip to content

Price / book at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
14.3×+11.7×
Gilead Sciences logo
Gilead SciencesGILD
7.4×+0.1×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
125.1×+108×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
+4.3×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
1.8×+0.9×

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$881.02M+32.6%
Enterprise value$857.94M+36.6%
P/E5.5×
P/S4.6×-99.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Calculated from Arbutus Biopharma Corporation’s reported figures.

Based on the most recent quarter.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's price / book?
Arbutus Biopharma Corporation (ABUS) reported price / book of 3.4× in Q1 2026.
How has Arbutus Biopharma Corporation's price / book changed year-over-year?
Arbutus Biopharma Corporation's price / book decreased by 60.0% year-over-year, from 8.4× to 3.4×.
What is the long-term trend for Arbutus Biopharma Corporation's price / book?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's price / book has grown at a 20.7% compound annual growth rate (CAGR), from 4.7× to 12.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.